Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab for Intestinal Behçet's Syndrome Complicated by Myelodysplastic Syndrome
NCT07582991Phase 2Completed
- Start
- Mar 2024
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ustekinumab in Behçet's disease (BD). Started Mar 2024; status: completed.
02
Drugs
ustekinumab
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on NCT07582991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07582991.